GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nexien BioPharma Inc (OTCPK:NXEN) » Definitions » ROIC %

Nexien BioPharma (Nexien BioPharma) ROIC % : -22.22% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Nexien BioPharma ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Nexien BioPharma's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -22.22%.

As of today (2024-05-16), Nexien BioPharma's WACC % is 4.19%. Nexien BioPharma's ROIC % is -89.51% (calculated using TTM income statement data). Nexien BioPharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Nexien BioPharma ROIC % Historical Data

The historical data trend for Nexien BioPharma's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexien BioPharma ROIC % Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROIC %
Get a 7-Day Free Trial -1,412.21 -3,995.45 -14,752.00 -386.38 -114.81

Nexien BioPharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -143.14 -127.19 -107.32 -98.61 -22.22

Competitive Comparison of Nexien BioPharma's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Nexien BioPharma's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexien BioPharma's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nexien BioPharma's ROIC % distribution charts can be found below:

* The bar in red indicates where Nexien BioPharma's ROIC % falls into.



Nexien BioPharma ROIC % Calculation

Nexien BioPharma's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Jun. 2023 is calculated as:

ROIC % (A: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2022 ) + Invested Capital (A: Jun. 2023 ))/ count )
=-0.283 * ( 1 - 0% )/( (0.222 + 0.271)/ 2 )
=-0.283/0.2465
=-114.81 %

where

Nexien BioPharma's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-0.052 * ( 1 - 0% )/( (0.232 + 0.236)/ 2 )
=-0.052/0.234
=-22.22 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nexien BioPharma  (OTCPK:NXEN) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Nexien BioPharma's WACC % is 4.19%. Nexien BioPharma's ROIC % is -89.51% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Nexien BioPharma ROIC % Related Terms

Thank you for viewing the detailed overview of Nexien BioPharma's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexien BioPharma (Nexien BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Nexien BioPharma Inc is a researcher and developer of cannabinoid-based pharmaceutical for various medical conditions and disorders, all under U.S. Food and Drug Administration development pathways.
Executives
Jeffrey Friedland other: Former 10% Owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Usa Inc. 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Inc. 10 percent owner 4340 E. KENTUCKY AVE., SUITE 206, GLENDALE CO 80246
Joseph F Aceto officer: VP Legal & IP Counsel 1617 NEWARK ROAD, KENNETT SQUARE PA 19348
Jeremy Robert Reeh officer: VP Translational Research 11 TANKARD LANE, WASHINGTON CROSSING PA 18977
Alexander Michael Wasyl director, officer: Chief Executive Officer 31 BEIDLER DRIVE, WASHINGTON CROSSING PA 18977
Frank J Manganella officer: VP Corporate Development 148-26 10TH AVENUE, WHITESTONE NY 11357
Clark Courtney Lynne director PO BOX 7801, ASPEN CO 81612
Lindy Snider director 408 BARBARA LANE, BRYN MAWR PA 19010
Robert I Goldfarb officer: Chief Operating Officer 230 GOLDEN BEACH DRIVE, GOLDEN BEACH FL 33160
Evan L Wasoff officer: Chief Financial Officer 101 WINGER DRIVE, NEDERLAND CO 80466
Alain D Bankier director 150 COLUMBUS AVENUE APT 17F, NEW YORK NY 10023
Richard S Greenberg director, 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Ivo Heiden director, 10 percent owner 2275 HUNTINGTON DRIVE, SUITE 851, SAN MARINO CA 91108